Trial Profile
Multicenter, Randomized, Single-blind, Placebo-controlled, Combined 2-fold Cross-over and Group-comparison, Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Oral Doses of BAY85 3934 in Subjects With Chronic Kidney Disease (CKD)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Molidustat (Primary)
- Indications Kidney disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 29 Apr 2016 Time frame for primary endpoints changed. For adverse events time frame changed from 30 days to 9 weeks, and for blood pressure time frame changed from day 1 to 9 weeks.
- 15 Mar 2014 New trial record